Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUEST platform study in systemic sclerosis-associated interstitial lung disease
2023-507129-40-00Phase 2Authorised
- Sponsor
- Scleroderma Research Foundation
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab and nerandomilast in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) (4 arms), sponsored by Scleroderma Research Foundation. Primary endpoint: Change in forced vital capacity. Planned start Aug 2024; status: authorised.
02
Drugs
amlitelimabnerandomilast
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2023-507129-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507129-40-00.